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Current goals in the acute treatment of heart failure are focused on pulmonary and systemic decongestion
with loop diuretics as the cornerstone of therapy. Despite rapid relief of symptoms in patients with acute
decompensated heart failure, after intravenous use of loop diuretics, the use of these agents has been consistently
associated with adverse events, including hypokalemia, azotemia, hypotension, and increased mortality. Two recent
randomized trials have shown that continuous infusions of loop diuretics did not offer benefit but were associated
with adverse events, including hyponatremia, prolonged hospital stay, and increased rate of readmissions. This
is probably due to the limitations of congestion evaluation as well as to the deleterious effects linked to drug
administration, particularly at higher dosage. The impaired renal function often associated with this treatment is not
extensively explored and could deserve more specific studies. Several questions remain to be answered about the
best diuretic modality administration, global clinical impact during acute and post-discharge period, and the role of
renal function deterioration during treatment. Thus, if loop diuretics are a necessary part of the treatment for acute
heart failure, then there must be an approach that allows personalization of therapy for optimal benefit and
avoidance of adverse events.Introduction
In patients with acute heart failure (AHF), the risk of
death or rehospitalization within 60 days from admission
ranges from 30 to 60 %, depending on the population
studied [1, 2]. The symptoms that drive hospital admis-
sion are linked to congestion, and loop diuretics are the
most common initial therapeutic approach (used in 90 %
of cases) [3, 4]. These agents promptly improve symptoms
and have been shown to reduce dyspnea scores and
peripheral edema [4, 5]. However, loop diuretics have
been associated with increased rates of mortality and
readmission in a graded fashion with cumulative dose
and with continuous infusions [6, 7]. It is unclear whether
this association is due to confounding by indication or
whether adverse events lead to clinically meaningful out-
comes accounting for these observations. In this context,
neither European Society of Cardiology nor American
College of Cardiology/American Heart Association guide-
lines provide any specific recommendation regarding
starting and maintaining dosage, oral or intravenous* Correspondence: palazzuoli2@unisi.it
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this article, unless otherwise stated.infusion, and time course of treatment [1]. Thus, despite
the clinical efficacy of these drugs in providing decon-
gestion and symptomatic improvement, several questions
remain to be answered about the optimal approach in any
given patient providing diuresis and decongestion but not
tipping the balance leading to acute kidney injury (AKI),
electrolyte disturbances, and worse outcomes.
Congestion in heart failure
It has been difficult to demonstrate a uniform benefit
with respect to any individual therapeutic intervention
in patients with AHF [3–6]. This is probably due to a
wide range of pathophysiologies that result in a common
phenotypic appearance of pulmonary congestion and
peripheral edema [8, 9]. Although pulmonary and sys-
temic congestion may be the most overt findings, these
may be the “tip of the iceberg” reflecting significant con-
gestion of multiple organs, including the kidneys. Many
cardiac and extracardiac factors can lead to congestion:
left ventricular (LV) adverse remodeling, hypertrophy,
and stiffness; coronary artery disease and microvascular
ischemia; decreased systemic vascular compliance; re-
duced venous capacitance and excessive preload; super-
imposed right ventricular dysfunction; and pulmonaryticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
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angiotensin activation, nervous sympathetic overdrive, in-
creased arginine-vasopressin activity, endothelin secretion,
and increased immune cell signaling. Clinically, the patient
with AHF can be categorized into a two-by-two table ac-
cording to good or poor systemic perfusion and to the
presence or absence of congestion [10]. Those with both
poor perfusion and congestion have the worst overall
risk for short- and long-term mortality as well as
worsened renal function after the initiation of intravenous
loop diuretics.
Beyond hemodynamic derangement, there are systemic
mechanisms that substantially contribute to congestion
status, including neurohormonal activation which works
to maintain organ perfusion and systemic pressure while
enhancing sodium and water retention. Combined, in-
creased vascular stiffness and reduced vein capacitance
enhance both preload and afterload with a consequent rise
in cardiac filling pressure that reflects on the pulmon-
ary circulation. Arterial vasoconstriction associated
with increased venous pressure affects the kidney, causing
hemodynamic and parenchymal alterations: renal blood
flow redistribution, tubuloglomerular feedback, tubule ob-
literation, and efferent arteriolar constriction which leads
to reduced salt and water excretion. Slow plasma refill
from extravascular to intravascular bed and overhydratedFig. 1 Potential factors contributing to the development of congestion in
pulmonary capillary wedge pressureinterstitium is another component: the intravascular
volume decreases only marginally by diuretic treat-
ment; in contrast, the interstitial volume has substan-
tial reduction.
Given the combination of hemodynamic and neuro-
hormonal factors, each patient has an individual risk of
AKI or type 1 cardiorenal syndrome after the first few
doses of intravenous loop diuretics [11]. A strong clinical
clue for risk of AKI is increased central venous pressure
and therefore intra-abdominal and renal congestion.
Elevated intra-abdominal pressure has recently been
debated as a causal contributor in congestion devel-
opment. Raised intra-abdominal pressure reduces ab-
dominal compliance, leading to intra-abdominal organ
compression due to reduced venous return and parenchy-
mal congestion [12]. Moreover, elevated intra-abdominal
pressure may raise central venous pressure, which conse-
quently increases cardiac preload (Fig. 1). If the degree of
diuresis exceeds the rate of plasma refill from the extra-
vascular space, then transient decreases in forward flow to
the kidney can occur with the same amount of venous
back pressure, precipitating tubuloglomerular feedback
and a reduction of glomerular filtration combined with
augmented sodium reabsorption. This causes an abrupt
reduction in urine output and then a rise in the plasma
pool of creatinine, urea, and other filtered substances.acute heart failure. LVEDP left ventricular end-diastolic pressure, PCWP
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tools in assessing this complex and dynamic pathophysi-
ology in each patient. Futuristic approaches involve the
use of non-invasive abdominal compartment monitoring,
bioimpedance, or real-time assessments of glomerular fil-
tration to establish the correct loop diuretic dosing and
management of other drugs.
Significance of worsening renal function during
treatment
The rates of AKI or type 1 cardiorenal syndrome range
from 20 to 70 %, depending on different definitions,
creatinine cutpoint values, and the study population
[13–15]. Loop diuretic administration, particularly higher
doses and continuous infusions, is associated with higher
rates of AKI. Loop diuretics markedly increase activation
of the renin-angiotensin and sympathetic nervous systems.
This phenomenon is mediated by two distinct mecha-
nisms: the inhibition of sodium chloride uptake into the
macula densa cells and the stimulation of prostacyclin that
further increases secretion of renin. Indirect effects of loop
diuretics include reductions of renal blood flow and en-
hanced proximal tubule sodium reabsorption in between
loop diuretic doses. Chronically, these cells hypertrophy
and counteract the effect of loop diuretics. Finally, aldos-
terone works at the collecting duct to recover remaining
sodium in the urine while increased arginine vasopressin
can recover as much as 25 % of the free water in urine
despite the use of loop diuretics. Elevated diuretic dosages
are associated with increased sympathetic overdrive medi-
ated by direct and indirect renin activity. Indirect effects
of diuretic are observed in several sites: at glomerulus by
reduction of renal blood flow, at proximal tubules by
increase of sodium resorption, and at collection duct by
aldosterone activity. All of these modifications lead to de-
livery of sodium to the distal nephron, increased sodium
reabsorption, and distal tubule hypertrophy. The above
functional and parenchymal kidney modifications could
potentially result in sudden creatinine increase and epider-
mal growth factor receptor reduction, amplifying the AKI
independently from primary kidney disease [16]. Two
recent reports have shown that impaired renal function
after discharge had a worse prognosis compared with in-
hospital AKI; the same reports suggested that, in the post-
discharge period, diuretic resistance can persist and that
renal function should also be monitored closely [17, 18].
The importance of renal function changes during hos-
pitalization and its relation to decongestion has been con-
firmed by a retrospective analysis of the ESCAPE trial
(Evaluation Study of Congestive Heart Failure and Pul-
monary Artery Catheterization Effectiveness Trial) in
which hemoconcentration as a marker of more intense
decongestion was associated with a better prognosis even
if increased blood urea nitrogen (BUN) was observed [19].Hence, there is a great need for methods to discern be-
tween transient changes in serum creatinine likely associ-
ated with overdiuresis on one hand and AKI with more
long-lasting and injurious insults to the kidney on the
other [20]. However, data from the Diuretic Optimization
Strategies Evaluation (DOSE) AHF Trial demonstrated
that patients randomly assigned to higher doses of loop
diuretics had higher rates of AKI but similar outcomes
with respect to rehospitalization and death [21]. Addition-
ally, in a recent prospective study including two groups of
patients receiving a high diuretic dosage in different ad-
ministrations (intermittent versus continuous), we found
that more active diuresis and weight loss were associated
with higher rates of AKI, increased risk of death, and re-
admission at 6 months [22]. When fluid removal exceeds
the rate of plasma refill in those undergoing ultrafiltration,
AKI can be observed in a similar fashion to that with loop
diuretics [23]. Other attempts to obtain effective decon-
gestion that reduces diuretic dosage by using other drugs
have recently failed: neither low-dose dopamine nor low-
dose nesiritide enhanced decongestion or improved renal
function [24]. These recent findings suggest that the rela-
tion between decongestion, transient or persistent AKI,
and diuretic management is poorly understood. Transient
AKI could be the mirror of more aggressive decongestion
and high diuretic administration, reflecting a temporal re-
duction of renal perfusion pressure and kidney overload.
Persistent AKI is likely due to effective hemodynamic
impairment, primitive renal injury, and more intense neu-
rohormonal activation, but this relation is not persuasive
enough and deserves specific analysis. A systematic ap-
proach able to recognize the two typologies of AKI (i.e.,
transient versus persistent and primary versus secondary)
should lead to a more appropriate diuretic administration.
Understanding the exact hemodynamic mechanism of
congestion, its nature and severity is a further target
to detect the correct diuretic dosage.
Loop diuretics and outcome
The administration of intravenous loop diuretics to
patients with heart failure (HF) and congestion results
typically in a prompt diuretic effect. In most patients,
the increased diuresis is accompanied by a decrease in
LV ventricular filling pressures and improvement of symp-
toms by reducing pulmonary capillary wedge pressure and
intra-alveolar edema [25]. When used in combination with
vasodilators, loop diuretics reduce ventricular remodeling
and mitral regurgitation, resulting in increased cardiac
output. In spite of these hemodynamic effects, no long-
lasting benefits were demonstrated with this approach
[26]. In population studies, after adjustments for possible
confounders, the highest diuretic quartile of loop diuretic
dosing remained a significant predictor of mortality [26].
An increased risk for in-hospital mortality and renal
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of intravenous loop diuretics compared with lower doses
[27, 28]. The Acute Decompensated Heart Failure Registry
(ADHERE) analysis confirmed that patients receiving the
lower doses had a lower risk of in-hospital mortality,
intensive care unit stay, prolonged hospitalization, or ad-
verse renal effects [29]. A meta-analysis by Abdel-Qadir
et al. including more than 4000 patients has demonstrated
a clear relation among discharge diuretic dosage and re-
current events over a mean 3-year follow-up period and
shown doubled mortality in the highest quartile compared
with the lowest [30]. In accordance with this study, the
ESCAPE Trial showed that patients submitted to higher
daily dosage (300 mg/day) had an unfavorable laboratory
pattern in terms of elevated natriuretic peptide levels, in-
creased creatinine and hyponatremia, and worsened clin-
ical outcomes. In the same analysis, the authors observed
an inverse linear relation between diuretic dosage and ad-
verse outcome and suggested the lowest dosage feasible to
resolve congestive symptoms [7]. As mentioned above,
these associations could all represent confounding by indi-
cation, meaning that the more severely ill require higher
doses of diuretics, particularly when urine output does not
respond, and hence could be at higher risk for adverse
outcomes independent of the utilization of loop diuretics.
As mentioned above, the DOSE trial, a prospective ran-
domized double-blind controlled trial with a two-by-two
factorial design that compared bolus versus continuous
infusion and low-dose versus high-dose strategies in a
large population, did not demonstrate any benefit (death
or hospitalization) of one strategy with respect to the
others: analysis regarding bolus versus continuous admin-
istration revealed a trend toward a higher rate of creatin-
ine increase in the continuous arm, although this has not
influenced outcome [21]. Finally, a recent Cochrane ana-
lysis showed that bolus infusion was related to both in-
creased urine output and fewer adverse effects compared
with continuous infusions; unfortunately, no data were
reported on long-term mortality and post-discharge
events [31]. Thus, it remains unclear whether high doses
or continuous infusions of loop diuretics cause harm; but
given all of the data to date, they are very unlikely to help
patients. Taken together, these findings suggest that higher
dosage administration of loop diuretics probably contrib-
utes to adverse events as well as serving as a proxy for
more severe disease which itself confers a poor prognosis.
This theory seems to be confirmed by a subanalysis of the
DOSE trial showing that patients with higher furosemide
dose experienced worse renal function, more advanced
symptoms, and New York Heart Association class. Be-
sides, the same authors demonstrated a close relation be-
tween higher diuretic dose and risk of rehospitalization
[32]. Further studies are warranted to determine whether
high-dose diuretics are responsible for worsening renalfunction and whether coexisting renal dysfunction could
be a marker of more severe HF.
Loop diuretics, decongestion, and acute kidney
injury
Baseline renal function and the dynamic change in
serum creatinine are related to short- and longer-term
outcomes. A recent observational study showed that cre-
atinine change during hospitalization was independently
associated with a higher risk of 1-year mortality. How-
ever, in patients with normal or mildly impaired renal
function, creatinine changes (ΔCr) (admission to 48–72
hours) were not significantly associated with mortality.
Interestingly, in this subgroup of patients, a decrease in
ΔCr was associated with worse outcomes. Perhaps a
transient deterioration of renal function is required to
relieve congestion and improve global symptom assess-
ment. Thus, the intricate cardio-renal axis relation is
much more confused by the diuretic administration that
could potentially amplify deleterious effects at the kidney
level. Studies in this field revealed contrasting results:
some authors did not observe a poor prognosis during
treatment in patients who experienced worsening renal
function [33]. Others believe that impaired renal function
during treatment is only the consequence of aggressive
fluid loss and decongestion. Aggressive decongestion asso-
ciated with plasma hemoconcentration is associated with
significant mortality reduction at 6 months, although an
increase in creatinine was observed [34, 35].
The only two studies evaluating congestion and renal
function during different diuretic strategy administration
are the DOSE trial and the Diur HF trial. In the DOSE
registry, patients submitted to higher dose and continu-
ous modality administration revealed an increase in cre-
atinine, although they experienced improvement in their
symptoms and significant decongestion signs compared
with low-dose administration. However, this study did
not clarify which treatment modality is better to improve
outcomes and renal function and showed no significant
difference in hard endpoints during the follow-up period.
Therefore, the authors did not report interactions between
patients’ baseline characteristics and the efficacy of either
intervention. The average dose administered was approxi-
mately 100 mg every 12 hours, and the average infusion
was around 10 mg/hour [21]. In clinical practice, par-
ticularly in patients with renal dysfunction and diur-
etic resistance, the more appropriate dose would be
up to 200 mg every 12 hours. Finally, follow-up mon-
itoring was stopped at 60 days, and no data regarding
changes in renal function during post-discharge period are
available.
Conversely, in the Diur HF Trial, mean diuretic regimen
was higher with respect to the DOSE patients; therefore,
continuous versus bolus administration was compared.
Fig. 2 Effects of renin-angiotensin-aldosterone and sympathetic
overdrive in different kidney sites
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veloping renal impairment during hospitalization was
observed. This occurs despite a significant reduction of B-
type natriuretic peptide (BNP) level and urine output in-
crease found in the continuous arm [22]. Although these
tests are excellent in aiding the clinical determination of
AHF and providing prognosis, it has been shown that a
reduction in BNP/N-terminal of the prohormone brain
natriuretic peptide (BNP/NT-proBNP) is not necessarily
associated with freedom from AKI or a reduction in the
risk for readmission or death over the short term. By
current analysis, it is not possible to define the better mo-
dality administration and dosing regimen: higher dose
should be prospectively tested monitoring decongestion
by weight loss, diuresis, and symptom score measurement
together with in-hospital and post-discharge renal func-
tion determination.
Pitfalls and potential strategies during treatment
Treating and solving congestion are among the principal
goals of AHF management. Persistence of congestion
and poor response to diuretic treatment are associated
with increased risk of mortality and threefold higher rate
of re-hospitalization [36, 37]. Because higher-dose regi-
mens have been related to adverse outcome, relevant
questions remain about the optimal use of diuretics to
obtain efficient decongestion. A post-hoc analysis from
DOSE and Cardiorenal Rescue Study in Acute Decompen-
sated (CARRESS) HF highlighted that higher levels of
plasma renin activity were associated with lower blood
pressure, azotemia, and hyponatremia in more advanced
HF [38]. A report by Testani et al. showed that BUN/
creatinine ratio but not creatinine increase alone was
associated with early adverse events [39]. These studies
suggest that neurohormonal activation and plasma volume
contraction due to poor plasma refill are major determi-
nants of short-term complications, including hypotension,
AKI, and hyponatremia [40] (Fig. 2).
To avoid these pitfalls, many strategies have been pro-
posed. The so-called breaking phenomena of loop diuretic
resistance could in theory be overcome by continuous
infusion. Sequential nephron blockade includes the con-
temporary use of loop diuretics together with thiazides
and aldosterone antagonists in order to obtain a stepwise
impairment of sodium reabsorption at multiple points
along the nephron. This strategy is prone to increased
risks of hypoperfusion, hypokalemia, and hyponatremia
[41]. Lastly, ultrafiltration of isotonic fluid could in theory
remove fluid at a rate to match plasma refill without
causing volume contraction or activation of neurohor-
monal systems [42]. This method may be beneficial in
congestive patients who are predicted to become
diuretic-resistant. Another optional strategy during
early phases of AHF management is the non-invasiveventilation (NIV) therapy. Although the potential
beneficial role of the current treatment is still under
debate, it is accepted for patients with low systolic
pressure values to improve respiratory gas exchanges.
Prior studies have been limited to patients with car-
diogenic shock and pulmonary edema and have pro-
vided conflicting results: data from the ADHERE
registry documented a reduced mortality rate with re-
spect to patients with pulmonary edema submitted to
endotracheal intubation together with reduced length
of hospital stay [43]. More recently, a cross-sectional
multicenter study confirmed previous findings under-
lying some difference in the use and application of
modalities [44]. Finally, the NIV treatment seems to
have beneficial effects, reducing the need for vaso-
active and inotropic therapies. All of these data sug-
gest that NIV should be a reasonable treatment
option in some specific AHF pictures characterized by
systemic hypoperfusion and low oxygenation status
[45]. NIV could potentially favor the reduction of
high dosage loop diuretic administration, avoiding fur-
ther decrease in blood pressure, although specific
studies appear mandatory to clarify the specific clas-
ses which deserve this treatment.
In the setting of neurohormonal activation and ad-
equate perfusion, nesiritide could play an adjunctive role
but does not have a broadly applied benefit in AHF [46].
It is possible that oral tolvaptan used in those with high
arginine vasopressin (copeptin) levels even in the ab-
sence of hyponatremia could be beneficial in prompting
an aquaresis before congestion worsens [47]. Both of
these approaches would call for a personalized approach
which is based on hemodynamic and biomarker profiles
and which has not been undertaken in clinical trials to
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ance before it occurs are needed to avoid excessive loop
diuretic use with either sequential pharmacologic neph-
ron blockade or ultrafiltration [48, 49]. Overall, a direct
measurement of hemodynamic changes in arterial and
venous districts to better understand the primary dysfunc-
tion and the venous or pulmonary congestion should be
applied by central venous pressure estimation and LV
filling and pulmonary pressure exertion. Congestion status
and intra- or extravascular fluid accumulation are other
important items deserving careful monitoring. This is
actually possible by the routine use of bioimpedance,
evaluation of vena cava collapse, and lung ultrasound [10]
(Fig. 3). Such tools will likely include advanced renal
physiologic imaging, advanced assessments of systemic
and hemodynamics in the intra-abdominal arteries and
veins, blood and urine biomarkers of kidney tubular func-
tion and injury, and lastly assessment of systemic neuro-
hormonal activation profiles (renin-angiotensin, arginine
vasopressin, sympathetic nervous system, endothelin,
and others).
Conclusions
Pulmonary and systemic congestion are inextricably
linked to renal function. Use of loop diuretics is clearly
playing a role in decongestion but at the same time is
probably precipitating AKI and type 1 cardiorenal syn-
dromes in patients at risk for worsened renal function
and poor outcomes. Future research using advanced
tools and personalized approaches for optimal outcomes
is needed. Broad applications of high-dose or continuous
infusion of loop diuretics or adjunctive use of inotropic
and new vasoactive therapies have not been associated
with improved outcomes. We propose an algorithm in-
cluding a metric measurement of decongestion with
concomitant evaluation of renin-angiotensin-aldosteroneFig. 3 Strategy for loop diuretic therapy optimization looking for
renal dysfunction fluid accumulation and hemodynamic status.
AKI acute kidney injurysystem activity and renal dysfunction mechanisms. This
approach would allow a better AHF treatment by actual-
izing the integrated actors of the cardio-renal axis.
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